Sanofi Commences Construction Of Insulin Facility In Frankfurt, Germany
(RTTNews) - Monday, Sanofi (SNY) commenced construction of a new state-of-the-art insulin manufacturing facility at its BioCampus in Frankfurt, Germany, leveraging advanced digital technologies and artificial intelligence across manufacturing and quality processes.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.